Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results

Processed 3,034 EsoGuard® tests and recognized revenue of $0.8 million in 1Q25Secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over$40 million in proforma cashConference call and webcast to be held today, May 14th, at 8:30 AM EDTNEW YORK, May 14, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today ...